Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway

Cancer Epidemiology

Volumn 38, Issue 6, 2014, Pages 765-772

  Khan, Arif ^a   Aljarbou, Ahmad N ^a   Aldebasi, Yousef H ^a   Faisal, Syed M ^b,c   Khan, Masood A ^a  

^a QASSIM UNIVERSITY   (Saudi Arabia)

^b Cornell University ^*  (United States)

^c UNIVERSITY OF HYDERABAD   (India)

Author keywords

Akt; FASN; Her2; PI3K; Resveratrol; SKBR 3

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; LIPOCORTIN 5; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RESVERATROL; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; STILBENE DERIVATIVE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INHIBITION KINETICS; MTT ASSAY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; BREAST NEOPLASMS; FEMALE; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STILBENES;

EID: 84912141641     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.09.006     Document Type: Article

References (73)

1. de Kok T.M., de Waard P., Wilms L.C., van Breda S.G. Antioxidative and antigenotoxic properties of vegetables and dietary phytochemicals: the value of genomics biomarkers in molecular epidemiology. Mol Nutr Food Res 2010, 54:208-217.
2. Bickers D.R., Athar M. Novel approaches to chemoprevention of skin cancer. J Dermatol 2000, 27:691-695.
3. Keloff G.J., Sigman C.C., Greenwald P.P. Cancer chemoprevention: progress and promise. Eur J Cancer 1999, 35:2031-2038.
4. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009, 2:409-418.
5. Kundu J.K., Surh Y.J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008, 269:243-261.
6. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
7. Sengottuvelan M., Viswanathan P., Nalini N. Chemopreventive effect of trans-resveratrol-a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis 2006, 27:1038-1046.
8. Kapadia G.J., Azuine M.A., Tokuda H., Takasaki M. Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis. Pharmacol Res 2002, 45:499-505.
9. Brown V.A., Patel K.R., Viskaduraki M., et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res 2010, 70:9003-9011.
10. Patel K.R., Brown V.A., Jones D.J., et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010, 70:7392-7399.
11. Joe A.K., Liu H., Suzui M., et al. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002, 8:893-903.
12. Narayanan B.A., Narayanan N.K., Re G.G., Nixon D.W. Differential expression of genes induced by resveratrol in LNCaP cells: p53-mediated molecular targets. Int J Cancer 2003, 104:204-212.
13. Ahmad N., Adhami V.M., Afaq F., Feyes D.K., Mukhtar H. Resveratrol causes WAF-1/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001, 7:1466-1473.
14. Stewart J.R., Ward N.E., Ioannides C.G., O'Brien C.A. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 1999, 38:13244-13251.
15. Tinhofer I., Bernhard D., Senfter M., et al. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J 2001, 15:1613-1615.
16. Mahyar-Roemer M., Kohler H., Roemer K. Role of Bax in resveratrol induced apoptosis of colorectal carcinoma cells. BMC Cancer 2002, 2:27-35.
17. Fontecave M., Lepoivre M., Elleingand E., Gerez C., Guittet D. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 1998, 421:277-279.
18. Opipari A.W., Tan L., Boitano A.E., Sorenson D.R., Aurora A., Liu J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004, 64:696-703.
19. Basly J.P., Marre-Fournier F., Le-Bail J.C., Habrioux G., Chulia A.J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 2000, 66:769-777.
20. Zhang S., Cao H.J., Davis F.B., et al. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer 2004, 91:178-185.
21. Nakagawa H., Kiyozuka Y., Uemura Y., et al. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J Cancer Res Clin Oncol 2001, 127:258-264.
22. Shimokawa T., Kumar M.V., Lane M.D. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc Natl Acad Sci USA 2002, 99:66-71.
23. Loftus T.M., Jaworsky D.E., Frehywot G.L., et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000, 288:2379-2381.
24. Kuhajda F.P., Pizer E.S., Li J.N., et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 2000, 97:3450-3454.
25. Sul H.S., Wang D. Nutritional and hormonal regulation of enzymes in fat synthesis: studies of fatty acid synthase and mitochondrial glycerol-3-phosphate acyltransferase gene transcription. Annu Rev Nutr 1998, 18:331-351.
26. Milgraum L.Z., Witters L.A., Pasternack G.R., Kuhajda F.P. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997, 3:2115-2120.
27. Alo P.L., Visca P., Trombetta G., et al. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 1999, 85:35-40.
28. Kuhajda F.P., Jenner K., Wood F.D., et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 1994, 91:6379-6383.
29. Jin Q., Yuan L.X., Boulbes D., et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 2010, 12:R96.
30. Vazquez-Martin A., Colomer R., Brunet J., Lupu R., Menendez J.A. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 2008, 41:59-85.
31. Menendez J.A., Vellon L., Mehmi I., et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004, 101:10715-10720.
32. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
33. Puig T., Vázquez-Martín A., Relat J., et al. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 2008, 109:471-479.
34. Pan M.H., Lin C.C., Lin J.K., Chen W.J. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen activated protein kinase cascade signaling. J Agric Food Chem 2007, 55:5030-5037.
35. Tian W.X. Inhibition of fatty acid synthase by polyphenols. Curr Med Chem 2006, 13:967-977.
36. Gnoni G.V., Paglialonga G. Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur J Clin Invest 2009, 39:211-218.
37. Li B.H., Ma X.F., Wang Y., Tian W.X. Structure-activity relationship of polyphenols that inhibit fatty acid synthase. J Biochem 2005, 138:679-685.
38. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
39. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991, 139:271-279.
40. Evens A.M., Prachand S., Shi B., et al. Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 2004, 10:1481-1491.
41. Khan A., Aijaz A.K., Dwivedi V., et al. Tuftsin augments antitumor efficacy of liposomised etoposide against fibrosarcoma in Swiss albino mice. Mol Med 2007, 13:266-276.
42. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
43. Sun S.Y., Hail N., Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004, 96:662-672.
44. Chan T.O., Rittenhouse S.E., Tsichlis P.N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999, 68:965-1041.
45. Rachid O., Alkhalaf M. Resveratrol regulation of PI3KAKT signaling pathway genes in MDA-MB-231 breast cancer cells. Cancer Genomics Proteomics 2006, 3:383-388.
46. Poolman T.M., Ng L.L., Farmer P.B., Manson M.M. Inhibition of the respiratory burst by resveratrol in human monocytes: correlation with inhibition of PI3K signalling. Free Radic Biol Med 2005, 39:118-132.
47. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
48. Wang S.C., Hung M.C. Transcriptional targeting of the HER2/neu oncogene. Drugs Today (Barc) 2000, 36:835-843.
49. Oliver F.J., de la Rubia G., Rolli V., et al. Importance of poly(ADPribose) polymerase and its cleavage in apoptosis: lesson from an uncleavable mutant. J Biol Chem 1998, 273:33533-33539.
50. Nahta R., Iglehart D., Kempkes B., Schmidt E.V. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 2002, 62:2267-2271.
51. Yu Q., Gen Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
52. She Q.B., Bode A.M., Ma W.Y., Chen V., Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 2001, 61:1604-1610.
53. Surh Y.J., Hurh Y.J., Kang J.Y., et al. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett 1999, 140:1-10.
54. Clement M.V., Hirpara J.L., Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes triggers Cd95 signalling-dependent apoptosis in human tumor cells. Blood 1998, 92:996-1002.
55. Soleas G.J., Grass L., Josephy P.D., Goldberg D.M., Diamandis E.P. A comparison of the anticarcinogenic properties of four red wine polyphenols. Clin Biochem 2002, 35:119-124.
56. Liu H., Zang C., Fenner M.H., et al. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood 2006, 107:3683-3692.
57. Roy P., Kalra N., Prasad S., George J., Shukla Y. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res 2009, 26:211-217.
58. Seeni A., Takahashi S., Takeshita K., et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 2008, 9:7-14.
59. Rangan V.S., Joshi A.K., Smith S. Mapping the functional topology of the animal fatty acid synthase by mutant complementation in vitro. Biochemistry 2001, 40:10792-10799.
60. Chirala S.S., Jayakumar A., Gu Z.W., Wakil S.J. Human fatty acid synthase: role of interdomain in the formation of catalytically active synthase dimmer. Proc Natl Acad Sci USA 2001, 98:3104-3108.
61. Joshi A.K., Witkowski A., Smith S. Mapping of functional interactions between domains of the animal fatty acid synthase by mutant complementation in vitro. Biochemistry 1997, 36:2316-2322.
62. Wang Y.Y., Kuhajda F.P., Li J., et al. Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer. J Exp Ther Oncol 2004, 4:101-110.
63. Alo P.L., Visca P., Botti C., et al. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol 2001, 116:129-134.
64. Carvalho M.A., Zecchin K.G., Seguin F., et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 2008, 123:2557-2565.
65. Kourtidis A., Srinivasaiah R., Carkner R.D., Brosnan M.J., Conklin D.S. Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res 2009, 11:R16.
66. Yoon S., Lee M.Y., Park S.W., et al. Upregulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 2007, 282:26122-26131.
67. Kumar-Sinha C., Ignatoski K.W., Lippman M.E., Ethier S.P., Chinnaiyan A.M. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003, 63:132-139.
68. Menendez J.A. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta 2010, 1801:381-391.
69. Menendez J.A., Lupu R., Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 2005, 18:375-385.
70. Menendez J.A., Vellon L., Lupu R. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 2005, 64:997-1001.
71. Xing X., Wang S.C., Xia W., et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000, 6:189-195.
72. Sabbisetti V., Di Napoli A., Seeley A., et al. p63 promotes cell survival through fatty acid synthase. PLoS ONE 2009, 4:e5877.
73. Grunt T.W., Wagner R., Grusch M., et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun 2009, 385:454-459.